Related Experiment Video
Updated: May 30, 2026

An Orthotopic Bladder Cancer Model for Gene Delivery Studies
Published on: December 1, 2013
Novel agents for advanced bladder cancer
Guru Sonpavde1, Aymen A Elfiky, Jonathan E Rosenberg
1Genitourinary Oncology Program, Texas Oncology, Veterans Affairs Medical Center, Baylor College of Medicine, 501 Medical Center Blvd, Webster, TX 77598, USA.
Abstract:
Conventional front-line platinum-based combination chemotherapy yields high response rates but suboptimal long-term outcomes for advanced transitional cell carcinoma. Salvage therapy is an unmet need with disappointing outcomes. The emergence of novel biologic agents offers the promise of improved outcomes. Neoadjuvant therapy preceding cystectomy for muscle-invasive bladder cancer provides an important paradigm and an interesting approach in developing novel agents. Patients who are not candidates for cisplatin require special attention. A multidisciplinary approach and collaboration among laboratory scientists, oncologists, urologists and radiation oncologists is necessary to make therapeutic advances. Recent and ongoing trials of novel chemotherapeutic and biologic agents are reviewed.
Related Concept Videos
Treatment Resistent Cancers
Treatment Resistant Cancers
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
Urinary Tract Calculi III: Medical Management
